KRAS and neoplasm: Most recently, Pant and colleagues demonstrated significant tumor biomarker response to KRAS-specific amphiphile vaccine for patients with pancreatic malignancy.12 Knowledge of the molecular alterations in PCLs and their application in clinical settings have been previously demonstrated to improve clinical outcomes.13 However, there are debates regarding when to use the molecular characterization of these samples.14 A closer look at the present guidelines is helpful in improving management plans for PC.